[go: up one dir, main page]

MX2017001331A - Composicion farmaceutica oral de isotretinoina. - Google Patents

Composicion farmaceutica oral de isotretinoina.

Info

Publication number
MX2017001331A
MX2017001331A MX2017001331A MX2017001331A MX2017001331A MX 2017001331 A MX2017001331 A MX 2017001331A MX 2017001331 A MX2017001331 A MX 2017001331A MX 2017001331 A MX2017001331 A MX 2017001331A MX 2017001331 A MX2017001331 A MX 2017001331A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
oral pharmaceutical
isotretinoin
present
preparing
Prior art date
Application number
MX2017001331A
Other languages
English (en)
Inventor
Rao Rajesh
Kumar Jain Satish
Barat Singh Romi
Kumar Fanda Anuj
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MX2017001331A publication Critical patent/MX2017001331A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una composición farmacéutica oral de isotretinoína con efecto reducido al alimento. La presente invención además se relaciona a un proceso para preparar la composición farmacéutica oral de la presente invención.
MX2017001331A 2014-07-31 2015-05-29 Composicion farmaceutica oral de isotretinoina. MX2017001331A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2158DE2014 2014-07-31
PCT/IB2015/054101 WO2016016742A1 (en) 2014-07-31 2015-05-29 Oral pharmaceutical composition of isotretinoin

Publications (1)

Publication Number Publication Date
MX2017001331A true MX2017001331A (es) 2017-05-23

Family

ID=55216820

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001331A MX2017001331A (es) 2014-07-31 2015-05-29 Composicion farmaceutica oral de isotretinoina.

Country Status (11)

Country Link
US (2) US9700535B2 (es)
EP (1) EP3174601A4 (es)
JP (1) JP2017521470A (es)
AU (1) AU2015294993A1 (es)
BR (1) BR112017001963A2 (es)
CA (1) CA2956831A1 (es)
MA (1) MA40447A (es)
MX (1) MX2017001331A (es)
RU (1) RU2017106013A (es)
WO (1) WO2016016742A1 (es)
ZA (1) ZA201700843B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017203365A1 (en) 2016-05-26 2017-11-30 Dr. Reddy's Laboratiories Ltd. Pharmaceutical compositions for treating acne
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
WO2022091140A1 (en) * 2020-11-01 2022-05-05 Idrs Labs Pvt Ltd Oral liquid pharmaceutical compositions of isotretinoin
JP2025534534A (ja) 2022-07-01 2025-10-16 アクロテック バイオファーマ インコーポレーティド イソトレチノインを含む医薬組成物、その調製のためのプロセス及びその使用
WO2024236523A1 (en) 2023-05-16 2024-11-21 Sun Pharmaceutical Industries Limited Once daily isotretinoin composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
DE60104206T2 (de) 2000-09-22 2005-09-22 Galephar M/F Halbfeste arzneizubereitung enthaltend isotretinoin
US20050129773A1 (en) * 2001-12-06 2005-06-16 Inderdeep Bhatia Isotretinoin nanoparticulate compositions
SE0303135D0 (sv) * 2003-11-25 2003-11-25 Lipocore Holding Ab Controlled food effect composition
EP2143421A1 (en) * 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
EP2432553A2 (en) * 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Liquid dosage forms of isotretinoin
WO2012053013A2 (en) * 2010-10-21 2012-04-26 Cadila Healthcare Limited Pharmaceutical compositions of anti-acne agents
US9078925B2 (en) * 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
JP2017516792A (ja) * 2014-05-29 2017-06-22 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． 経口イソトレチノイン医薬組成物
MA40781A (fr) * 2014-10-01 2017-08-08 Sun Pharmaceutical Ind Ltd Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
EP3302412A4 (en) * 2015-05-25 2019-01-16 Sun Pharma PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN FOR ORAL INJECTION ONCE DAILY

Also Published As

Publication number Publication date
US20170258748A1 (en) 2017-09-14
WO2016016742A1 (en) 2016-02-04
MA40447A (fr) 2016-02-04
AU2015294993A1 (en) 2017-02-16
JP2017521470A (ja) 2017-08-03
BR112017001963A2 (pt) 2017-11-21
CA2956831A1 (en) 2016-02-04
US9700535B2 (en) 2017-07-11
EP3174601A4 (en) 2018-01-10
ZA201700843B (en) 2018-04-25
EP3174601A1 (en) 2017-06-07
RU2017106013A (ru) 2018-08-28
US20160081964A1 (en) 2016-03-24
RU2017106013A3 (es) 2018-11-14

Similar Documents

Publication Publication Date Title
GEP20207074B (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
IN2014CH00247A (es)
MA40313A (fr) Composition pharmaceutique à base d'isotrétinoïne destinée à la voie orale
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
EP3166931A4 (en) An improved process for the preparation of enzalutamide
IN2013MU00646A (es)
MX2017003301A (es) Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario.
IL248267B (en) A process for preparing converted cycloserines
EP3230280A4 (en) Process for preparation of luliconazole
EP3148979A4 (en) Process for preparation of canagliflozin
MX2017001487A (es) Sofosbuvir en forma cristalina y proceso para su preparacion.
IN2014MU00455A (es)
HUE058627T2 (hu) Új eljárás nagy tisztaságú prosztaglandinok elõállítására
SI3160985T1 (sl) Postopek za pripravo D-arginil-2,6-dimetil-L-tirosil-L-lisil-L- fenilalaninamida
MA40447A (fr) Composition pharmaceutique orale d'isotrétinoïne
EP3196186A4 (en) Method for producing vapor composition containing lactic acid
MA40312A (fr) Composition pharmaceutique orale d'isotrétinoïne
PL3236764T3 (pl) Sposób wytwarzania kompozycji przyprawowych
EP3182981A4 (en) Process for the production of isomaltooligosaccharides
IL247443B (en) Process for the preparation of 5-fluorotryptophol
MX382631B (es) Proceso para la preparacion de derivados dihidroisoxazol.
PL3223799T3 (pl) Sposób otrzymywania kompozycji składnik farmaceutyczny-polimer
PL3126111T3 (pl) Maszyna do produkcji produktów ceramicznych
EP3124049A4 (en) Process for producing composition of emulsion preparation type
HUP1400518A2 (hu) Eljárás tofacitinib elõállítására